Rituximab appears to offer no long term benefit to patients with primary Sjögren syndrome (pSS), according to an article published in Annals of Internal Medicine.pSS is a chronic autoimmune disorder characterized by dryness of the eyes and mouth. Up to half of patients have systemic involvement, with fatigue being a symptom associated with significant disability. No systemic treatment has been proved to significantly improve symptoms. Mounting evidence on B cell involvement in pSS suggests that B-cell depletion could be an effective treatment for pSS.
No comments:
Post a Comment